Incyte (INCY) Non-Current Deffered Revenue (2010 - 2015)
Incyte's (INCY) quarterly Non-Current Deffered Revenue came in at $2.9 million in Q3 2015, down 81.76% YoY from $15.7 million in Q3 2014, and down 52.84% on a QoQ basis from $6.1 million in Q2 2015.
Incyte (INCY) Non-Current Deffered Revenue (2010 - 2015) Analysis & Trends
Incyte (INCY) has 6 years of Non-Current Deffered Revenue data on file, last reported at $2.9 million in Q3 2015.
- Quarterly Non-Current Deffered Revenue fell 81.76% year-over-year to $2.9 million in Q3 2015, while the trailing twelve-month figure through Sep 2015 was $2.9 million (down 81.76% YoY) and the FY2014 annual result came in at $12.5 million, down 50.68% from the prior year.
- Non-Current Deffered Revenue eased to $2.9 million in Q3 2015, from $6.1 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $154.5 million in Q1 2011 to a low of $2.9 million in Q3 2015.
- A 5-year average of $51.4 million and a median of $31.8 million in 2013 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2013 — Non-Current Deffered Revenue plunged 33.63% — and 2015, when it plunged 81.76%.
- Tracing INCY's Non-Current Deffered Revenue over 5 years: stood at $104.3 million in 2011, then slumped by 63.34% to $38.2 million in 2012, then slumped by 33.63% to $25.4 million in 2013, then plunged by 50.68% to $12.5 million in 2014, then sank by 77.07% to $2.9 million in 2015.
- The last three Non-Current Deffered Revenue figures came in at $2.9 million (Q3 2015), $6.1 million (Q2 2015), and $9.3 million (Q1 2015), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 2.87 Mn |
| Jun 30, 2015 | 6.08 Mn |
| Mar 31, 2015 | 9.30 Mn |
| Dec 31, 2014 | 12.51 Mn |
| Sep 30, 2014 | 15.73 Mn |
| Jun 30, 2014 | 18.94 Mn |
| Mar 31, 2014 | 22.15 Mn |
| Dec 31, 2013 | 25.37 Mn |
| Sep 30, 2013 | 28.58 Mn |
| Jun 30, 2013 | 31.80 Mn |
| Mar 31, 2013 | 35.01 Mn |
| Dec 31, 2012 | 38.23 Mn |
| Sep 30, 2012 | 54.06 Mn |
| Jun 30, 2012 | 70.80 Mn |
| Mar 31, 2012 | 87.54 Mn |
| Dec 31, 2011 | 104.27 Mn |
| Sep 30, 2011 | 121.01 Mn |
| Jun 30, 2011 | 137.75 Mn |
| Mar 31, 2011 | 154.48 Mn |
| Dec 31, 2010 | 171.22 Mn |